About Enterra Medical
Our company’s mission
Enterra Medical was founded to help more people with chronic gastroparesis find relief by advancing technology, expanding clinical science, and accelerating access to Enterra® Therapy.
Hope and help for gastroparesis patients
In 2022, Enterra Medical was formed to focus on helping more gastroparesis patients find relief through Enterra Therapy—a device originally developed by Medtronic and approved by the FDA in 2000 under a Humanitarian Device exemption. While Medtronic continues to be an important partner, Enterra Medical is an independent entity dedicated to leading the way in therapy innovation and support for people living with gastroparesis.
Implanted in more than 15,000 patients, Enterra Therapy is the first and only device designed to reduce the nausea and vomiting associated with diabetic or idiopathic gastroparesis through gastric electrical stimulation (GES).
Through the power of Enterra Therapy, Enterra Medical seeks to equip healthcare providers with a reversible, minimally-invasive advanced treatment option so that they can finally offer hope—and help—to patients living with gastroparesis.
NEXT : Challenge of gastroparesis
MKT-D-0006, Rev L
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?